BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ...

ATTR-CM treatment options narrowed after AstraZeneca and Ionis revealed their gene-silencing drug Wainua (eplontersen) failed ...

BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its ...

Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together ...

Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and ...

While investors have long treated the pharmaceuticals’ industry with caution, those that avoid the sector are missing out on clear opportunities. While navigating the fast-developing industry is not ...

To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...

Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an ...

BridgeBio's lead drug Attruby (acoramidis) is tracking a steep commercial ramp, alongside $500 million share repurchase program and three additional NDAs planned for 2026. Citi's caution stands ...

BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three ...